A detailed history of Geode Capital Management, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,098,097 shares of EXAS stock, worth $216 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,098,097
Previous 2,969,890 4.32%
Holding current value
$216 Million
Previous $205 Million 36.18%
% of portfolio
0.01%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$41.33 - $74.26 $5.3 Million - $9.52 Million
128,207 Added 4.32%
3,098,097 $131 Million
Q1 2024

May 13, 2024

BUY
$56.27 - $73.77 $5.04 Million - $6.61 Million
89,628 Added 3.11%
2,969,890 $205 Million
Q4 2023

Feb 13, 2024

BUY
$59.06 - $75.72 $6.61 Million - $8.47 Million
111,911 Added 4.04%
2,880,262 $213 Million
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $4.77 Million - $7.16 Million
72,311 Added 2.68%
2,768,351 $189 Million
Q2 2023

Aug 11, 2023

BUY
$62.68 - $95.05 $6.58 Million - $9.98 Million
104,983 Added 4.05%
2,696,040 $253 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $4.34 Million - $6.5 Million
91,883 Added 3.68%
2,591,057 $176 Million
Q4 2022

Feb 13, 2023

BUY
$30.35 - $53.15 $3.84 Million - $6.73 Million
126,538 Added 5.33%
2,499,174 $124 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $764,178 - $1.18 Million
23,903 Added 1.02%
2,372,636 $77 Million
Q2 2022

Aug 12, 2022

BUY
$35.61 - $76.23 $3.01 Million - $6.44 Million
84,500 Added 3.73%
2,348,733 $92.4 Million
Q1 2022

May 13, 2022

BUY
$57.56 - $82.54 $5.31 Million - $7.62 Million
92,267 Added 4.25%
2,264,233 $158 Million
Q4 2021

Feb 11, 2022

BUY
$72.5 - $100.68 $5.57 Million - $7.73 Million
76,790 Added 3.67%
2,171,966 $169 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $139,420 - $191,657
1,545 Added 0.07%
2,095,176 $200 Million
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $14.3 Million - $21.3 Million
153,054 Added 7.89%
2,093,631 $260 Million
Q1 2021

May 12, 2021

BUY
$116.57 - $155.01 $24.4 Million - $32.4 Million
209,172 Added 12.08%
1,940,577 $255 Million
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $15 Million - $21.5 Million
151,055 Added 9.56%
1,731,405 $229 Million
Q3 2020

Nov 13, 2020

SELL
$72.92 - $102.01 $355,557 - $497,400
-4,876 Reduced 0.31%
1,580,350 $161 Million
Q2 2020

Aug 13, 2020

SELL
$55.75 - $92.75 $1.13 Million - $1.87 Million
-20,183 Reduced 1.26%
1,585,226 $138 Million
Q1 2020

May 14, 2020

BUY
$37.9 - $104.44 $1.27 Million - $3.5 Million
33,528 Added 2.13%
1,605,409 $93 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $14.5 Million - $18.6 Million
186,817 Added 13.49%
1,571,881 $145 Million
Q3 2019

Nov 12, 2019

BUY
$90.37 - $122.49 $3.18 Million - $4.3 Million
35,143 Added 2.6%
1,385,064 $125 Million
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $6.41 Million - $8.45 Million
71,590 Added 5.6%
1,349,921 $159 Million
Q1 2019

May 14, 2019

BUY
$61.98 - $96.5 $4.99 Million - $7.77 Million
80,491 Added 6.72%
1,278,331 $111 Million
Q4 2018

Feb 13, 2019

BUY
$56.04 - $82.66 $3.87 Million - $5.71 Million
69,128 Added 6.12%
1,197,840 $75.6 Million
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $658,772 - $1.1 Million
13,642 Added 1.22%
1,128,712 $89.1 Million
Q2 2018

Aug 14, 2018

SELL
$37.84 - $69.96 $414,196 - $765,782
-10,946 Reduced 0.97%
1,115,070 $66.7 Million
Q1 2018

May 15, 2018

BUY
$39.82 - $57.53 $1.09 Million - $1.57 Million
27,376 Added 2.49%
1,126,016 $45.4 Million
Q4 2017

Feb 13, 2018

BUY
$46.49 - $60.51 $1.14 Million - $1.49 Million
24,614 Added 2.29%
1,098,640 $57.7 Million
Q3 2017

Nov 14, 2017

BUY
$37.05 - $47.12 $363,460 - $462,247
9,810 Added 0.92%
1,074,026 $50.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
1,064,216
1,064,216 $37.6 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.